Clinical Trial Update: Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of GV 550 for acute adenoviral keratoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoviral Keratoconjunctivitis

Drugs mentioned

• GV 550

Snippet

Sponsor: Laboratoires Thea | Conditions: Acute Adenoviral Keratoconjunctivitis | Phase 2 | Status: COMPLETED